Prognostic value of pretreatment inflammatory markers in variant histologies of the bladder: is inflammation linked to survival after radical cystectomy?
Biomarker
Patient selection
Radical cystectomy
Variant histology
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
27
06
2020
accepted:
03
10
2020
pubmed:
22
10
2020
medline:
12
1
2022
entrez:
21
10
2020
Statut:
ppublish
Résumé
To investigate differences in standard preoperative inflammatory markers in patients with urothelial carcinoma (UC) and variant histologies undergoing radical cystectomy (RC) and determine its impact on survival. Patients undergoing RC at an academic high-volume center were retrospectively analyzed. Preoperatively taken CRP, leukocytes, hemoglobin (Hb), and thrombocytes were analyzed as routine inflammatory biomarkers. Log-rank tests and Kruskal-Wallis analysis were used to calculate for differences in survival and in blood levels of biomarkers. 886 patients with complete follow-up and UC or variant histology underwent RC at our institution between 2004 and 2019. Although variant histology presents with significantly higher t stage than UC, cancer-specific survival (CSS) of UC (1-year-CSS: 93%) is not significantly different to variant histology of UC with squamous differentiation (UCSD, 1-year-CSS: 81%), squamous cell carcinoma (SCC, 1-year-CSS: 82%), and adenocarcinoma (AC, 1-year-CSS: 81%). In UC, alterations in all biomarkers except leukocytes beyond routine cut-off values were associated with poor survival (p < 0.01), whereas Hb beyond cut-off values are associated with poor prognosis in SCC (p < 0.05). CRP levels are significantly elevated in UCSD and SCC at time of surgery compared to UC (p < 0.05). Inflammatory biomarkers reveal distinctive patterns across UC and variant histologies of bladder cancer. As inflammation might play an important role in cancer progression, further research is warranted to understand those molecular mechanisms and their potential therapeutic impact in variant histology of bladder cancer.
Identifiants
pubmed: 33084922
doi: 10.1007/s00345-020-03482-8
pii: 10.1007/s00345-020-03482-8
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2537-2543Informations de copyright
© 2020. Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Siegel RL, Miller KD, Jemal A (2020) Cancer statistics CA: a cancer journal for clinicians. J Nat Compreh Cancer Network 70:7–30
Moschini M, D’Andrea D, Korn S et al (2017) Characteristics and clinical significance of histological variants of bladder cancer. Nat Rev Urol 14:651–668
doi: 10.1038/nrurol.2017.125
Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs-part b: prostate and bladder tumours. Eur Urol 70:106–119
doi: 10.1016/j.eururo.2016.02.028
Amin MB (2009) Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Modern Pathol J US Ca 22(2):96–118
doi: 10.1038/modpathol.2009.26
Abol-Enein H, Kava BR, Carmack AJ (2007) Nonurothelial cancer of the bladder. Urology 69:93–104
doi: 10.1016/j.urology.2006.08.1107
Zaghloul MS, Nouh A, Nazmy M et al (2006) Long-term results of primary adenocarcinoma of the urinary bladder: a report on 192 patients. Urol Oncol 24:13–20
doi: 10.1016/j.urolonc.2005.05.027
Horwich A, Babjuk M, Bellmunt J et al (2019) EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. Ann Oncol Off J Euro Soc Med Oncol 30:1697–1727
doi: 10.1093/annonc/mdz296
Shapur NK, Katz R, Pode D et al (2011) Is radical cystectomy mandatory in every patient with variant histology of bladder cancer. Rare Tumors 3:e22
doi: 10.4081/rt.2011.e22
Willis DL, Fernandez MI, Dickstein RJ et al (2015) Clinical outcomes of cT1 micropapillary bladder cancer. J Urol 193:1129–1134
doi: 10.1016/j.juro.2014.09.092
Schulz GB, Grimm T, Buchner A et al (2018) Surgical high-risk patients With ASA >/= 3 undergoing radical cystectomy: morbidity, mortality, and predictors for major complications in a high-volume tertiary center. Clini Genit Cancer 16:e1141–e1149
doi: 10.1016/j.clgc.2018.07.022
Schulz GB, Grimm T, Buchner A et al (2017) Prognostic value of the preoperative platelet-to-leukocyte ratio for oncologic outcomes in patients undergoing radical cystectomy for bladder cancer. Clin Genit Cancer 15:e915–e921
doi: 10.1016/j.clgc.2017.05.009
Jokisch JF, Grimm T, Buchner A et al (2020) Preoperative thrombocytosis in patients undergoing radical cystectomy for urothelial cancer of the bladder: an independent prognostic parameter for an impaired oncological outcome. Urol Int 104:36–41
doi: 10.1159/000500729
Grimm T, Buchner A, Schneevoigt B et al (2016) Impact of preoperative hemoglobin and CRP levels on cancer-specific survival in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: results of a single-center study. World J Urol 34:703–708
doi: 10.1007/s00345-015-1680-7
Xylinas E, Rink M, Robinson BD et al (2013) Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur J Cancer 49:1889–1897
doi: 10.1016/j.ejca.2013.02.001
Moschini M, Dell’Oglio P, Luciano R et al (2017) Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. Urol Oncol 35:335–341
doi: 10.1016/j.urolonc.2016.12.006
Rodler S, Apfelbeck M, Stief C, Heinemann V, Casuscelli J (2020) Lessons from the COVID-19 pandemic - will virtual patient management reshape uro-oncology in Germany? Eur J Cancer 22:19–34
Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet (London, England) 387:1909–1920
doi: 10.1016/S0140-6736(16)00561-4
Tripathi A, Grivas P (2020) The utility of next generation sequencing in advanced urothelial carcinoma. Eur Urol Focus 6:41–44
doi: 10.1016/j.euf.2019.08.016
Rodler S, Buchner A, Stief CG, Heinemann V, Staehler M, Casuscelli J (2020) Patients perspective on digital technologies in advanced genitourinary cancers. Clin Genit Cancer 1:8
Alfred Witjes J, Lebret T, Comperat EM et al (2017) Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 71:462–475
doi: 10.1016/j.eururo.2016.06.020
Aziz A, Rink M, Gakis G et al (2014) Preoperative C-reactive protein in the serum: a prognostic biomarker for upper urinary tract urothelial carcinoma treated with radical nephroureterectomy. Urol Int 93:352–360
doi: 10.1159/000362248
Ku JH, Kang M, Kim HS, Jeong CW, Kwak C, Kim HH (2015) The prognostic value of pretreatment of systemic inflammatory responses in patients with urothelial carcinoma undergoing radical cystectomy. Br J Cancer 112:461–467
doi: 10.1038/bjc.2014.631
Ojerholm E, Smith A, Hwang WT et al (2017) Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: assessing prognostic and predictive value in SWOG 8710. Cancer 123:794–801
doi: 10.1002/cncr.30422
Tampa M, Mitran MI, Mitran CI et al (2018) Mediators of inflammation - a potential source of biomarkers in oral squamous cell carcinoma. J Immunol Res 18:1061780
Lu CC, Chang KW, Chou FC, Cheng CY, Liu CJ (2007) Association of pretreatment thrombocytosis with disease progression and survival in oral squamous cell carcinoma. Oral Oncol 43:283–288
doi: 10.1016/j.oraloncology.2006.03.010
Madeddu C, Gramignano G, Astara G et al (2018) Pathogenesis and treatment options of cancer related anemia: perspective for a targeted mechanism-based approach. Front Physiol 9:1294
doi: 10.3389/fphys.2018.01294
Dolan RD, McSorley ST, Park JH et al (2018) The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores. Br J Cancer 119:40–51
doi: 10.1038/s41416-018-0095-9
Nukui A, Kamai T, Arai K et al (2020) Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density. Cancer Immunol Immunother 69:689–702
doi: 10.1007/s00262-020-02499-7